Publications by authors named "M R Dillingh"
There is a need for antidiabetic agents successfully targeting insulin sensitivity and treating obesity control at the same time. The aim of this first-in-human study was (a) to evaluate safety and tolerability, (b) to evaluate pharmacokinetics and (c) to assess indications of receptor engagement of single ascending doses of KBP-042, a dual amylin and calcitonin receptor agonist (DACRA) that has shown promising preclinical data, with superior activity in terms of typical amylin-induced responses including reduction of food intake, weight loss and gluco-regulatory capacities. A randomised double-blind placebo-controlled single ascending dose study was performed with six dose levels of KBP-042 (5, 7.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of low- to moderate-dose endotoxin (LPS) on the endothelium and kidney function in healthy males, focusing on both the magnitude of the response and timing.
- It was a randomized, double-blind, placebo-controlled trial, where participants received either LPS or a placebo, measuring various inflammatory and kidney injury markers.
- Results showed significant inflammatory responses with higher LPS doses, but no clinically relevant kidney damage, suggesting this model could be beneficial for future clinical research.
Background: DNA viruses such as HPV rely on K influx for replication. Both digoxin and furosemide inhibit the K influx by interacting with cell membrane ion co-transporters (Na /K -ATPase and Na -K -2Cl co-transporter-1, respectively). We therefore hypothesized that these two compounds in a topical formulation may be valuable in the treatment of HPV-induced warts.
View Article and Find Full Text PDFArticle Synopsis
- ONS-3010, developed by Oncobiologics as a biosimilar to Humira, underwent a phase I study to compare its pharmacokinetics, safety, and immunogenicity to both EU and US versions of Humira in healthy volunteers.
- The study involved 198 participants who received a single dose of either ONS-3010 or Humira, with results showing similar pharmacokinetic profiles and immune responses across treatment groups.
- Additionally, the research highlighted the effectiveness of ONS-3010 in significantly lowering TNFα levels and interleukin-8 release in response to specific immune challenges, indicating its potential for further clinical development.
Abnormal fibrogenic repair response upon alveolar injury is believed to play an important role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). PRM-151 (recombinant human pentraxin-2, also known as serum amyloid P), has been shown to reduce fibrosis in preclinical lung fibrosis models, and was well tolerated with a favourable pharmacokinetic profile in an earlier single-dose phase I study.A randomised, double-blind, placebo-controlled, multiple ascending dose trial was performed to assess the tolerability and pharmacokinetic and pharmacodynamic characteristics of multiple doses of PRM-151 in IPF patients.
View Article and Find Full Text PDF